Stock listing

A0X789 Stock Price, News, Filings & Events — Ironwood Pharmaceuticals, Inc.

Selected listing: A0X789 · LSX · EUR · DE

This page tracks Ironwood Pharmaceuticals, Inc.'s A0X789:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A0X789:LSX. A0X789:LSX is the stock-level entry point for investors researching Ironwood Pharmaceuticals, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Ironwood Pharmaceuticals, Inc. (ticker: IRWD) is a public company based in the United States, specializing in the development and commercialization of innovative therapies for gastrointestinal diseases. With a market capitalization of approximately $610.7 million, Ironwood focuses on addressing unmet medical needs in this area. The company is committed to improving patient outcomes through its research and product...

A0X789:LSXEURDEUpdated September 11, 2026

Ticker: A0X789:LSX
Asset type: Stock
Market cap: $674.2M
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: LSX
Currency: EUR

Ironwood Pharmaceuticals, Inc. A0X789:LSX stock context

Latest news from Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 3, 2026

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

August 6, 2026

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

July 30, 2026

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and...

July 14, 2026

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

May 27, 2026

All Ironwood Pharmaceuticals, Inc. news →

Ironwood Pharmaceuticals, Inc. earnings calls

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call

August 6, 2026 · Replay with transcript and chapters

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2026 Earnings Call

May 7, 2026 · Replay with transcript and chapters

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2025 Earnings Call

February 25, 2026 · Replay with transcript and chapters

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call

February 27, 2025 · Replay with transcript and chapters

Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call

November 7, 2024 · Replay with transcript and chapters

Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2024 Earnings Call

May 9, 2024 · Replay with transcript and chapters

Research Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. investor report

Review AI stock analysis and investor report context for A0X789:LSX.

Ironwood Pharmaceuticals, Inc. company profile

View the public company page for Ironwood Pharmaceuticals, Inc. on 6ix.

Ironwood Pharmaceuticals, Inc. news

Read company news and market updates connected to Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Ironwood Pharmaceuticals, Inc..